Barlev A, Song X, Ivanov B, Setty V, Chung K: Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010, 16: 693-702.
Google Scholar
Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80: 1588-1594. 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G
Article
Google Scholar
Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27: 165-176. 10.1053/ctrv.2000.0210
Article
Google Scholar
Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12: 6243s-6249s. 10.1158/1078-0432.CCR-06-0931
Article
Google Scholar
Costa L, Badia X, Chow E, Lipton A, Wardley A: Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 2008, 16: 879-889. 10.1007/s00520-008-0418-0
Article
Google Scholar
Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM, Chouaid C: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol 2011, 6: 576-582. doi:10.1097/JTO.0b013e318206a1e3
Article
Google Scholar
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G: The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004, 67: 390-396. 10.1159/000082923
Article
Google Scholar
Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G: Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006, 4: 341-347.
Google Scholar
DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F: Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007, 15: 869-876. 10.1007/s00520-006-0203-x
Article
Google Scholar
European Medicines Agency: Denosumab (XGEVA) summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf
Google Scholar
Expósito J, Jaen J, Alonso E, Tovar I: Use of palliative radiotherapy in brain and bone metastases (VARA II study). Radiat Oncol 2012, 7: 131. doi:10.1186/1748-717X-7-131
Article
Google Scholar
Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, Costa L, Marcelo F, Peralta F, Furtado I, Pina F, Albuquerque C, Santos A, Passos-Coelho JL: Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health 2011, 14: 499-505. doi:10.1016/j.jval.2010.11.014
Article
Google Scholar
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377: 813-822. 10.1016/S0140-6736(10)62344-6
Article
Google Scholar
Gunther O, Body JJ, Sleeboom H, Hechmati G, Pereira J, Maniadakis N, Terpos E, Acklin YP, Finek J, Mossman T, Von Moos R: Health resource utilisation (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BMS): results from a retrospective, multinational European study. Value Health 2011, 14: A455-A456. doi:10.1016/j.jval.2011.08.1216
Article
Google Scholar
Hechmati G, Hoefeler H, Bahl A, Lüftner D, Lorusso V, Garzón Rodriguez C, Ashcroft J, Suenaert P, Wei R, Durán I: Skeletal-related events in patients with bone metastases lead to considerable health resource utilisation in Europe: analysis of a multinational observational study. Value Health 2011, 14: 168.
Article
Google Scholar
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H: Randomized, double-blind study of denosumab versus zoledronic Acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29: 1125-1132. 10.1200/JCO.2010.31.3304
Article
Google Scholar
Katzer A, Meenen NM, Grabbe F, Rueger JM: Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002, 122: 251-258. 10.1007/s00402-001-0359-2
Article
Google Scholar
Lage MJ, Barber BL, Harrison DJ, Jun S: The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008, 14: 317-322.
Google Scholar
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88: 1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z
Article
Google Scholar
Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010, 184: 162-167. 10.1016/j.juro.2010.03.034
Article
Google Scholar
Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010, 19: 755-760. doi:10.1111/j.1365-2354.2009.01135.x
Article
Google Scholar
Royal College of Radiologists: Single fraction radiotherapy for bone metastases. 2007. . Accessed 2 November 2012 http://www.rcr.ac.uk/docs/oncology/pdf/bonemetsreport.pdf
Google Scholar
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110: 1860-1867. 10.1002/cncr.22991
Article
Google Scholar
Schulman KL, Kohles J: Economic burden of metastatic bone disease in the U.S. Cancer 2007, 109: 2334-2342. 10.1002/cncr.22678
Article
Google Scholar
Steliarova-Foucher E, O’Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: cancer incidence, mortality, prevalence and survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. 2012. . Accessed 25 March 2013 http://eco.iarc.fr
Google Scholar
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer R, Lichinitser M, Fujiwara Y, Yardley D, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A, Investigators obotBCSS: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28: 5132-5139. 10.1200/JCO.2010.29.7101
Article
Google Scholar
Svendsen ML, Gammelager H, Svaerke C, Yong M, Chia VM, Christiansen CF, Fryzek JP: Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clin Epidemiol 2013, 5: 97-103. doi:10.2147/CLEP.S42325 clep-5-097
Google Scholar
Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed? BMJ 2000, 320: 1197-1200. 10.1136/bmj.320.7243.1197
Article
Google Scholar
Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA: Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42: 164-175. 10.1097/01.mlr.0000108746.69256.45
Article
Google Scholar
Williams MV, Summers ET, Drinkwater K, Barrett A: Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005. Clin Oncol (R Coll Radiol) 2007, 19: 273-286. doi:10.1016/j.clon.2007.03.011
Article
Google Scholar